>5.5 million people in the US diagnosed with dementia due to AD

- 1 in 10 seniors is diagnosed with AD dementia
- If unaddressed, the number of cases is expected to more than double by 2050

Older African Americans are 2X as likely to have Alzheimer’s disease and other dementias as older whites

The US health care system infrastructure for an AD disease modifying treatment faces significant challenges and capacity constraints to be overcome (Rand report 2018). Underserved AD populations will likely see greater impact.

**AD Patient Journey**

**DETECTION**
- Detecting people who may benefit from treatment for cognitive impairment

**ASSESSMENT**
- Assessing people for cognitive impairment and/or a high likelihood of AD pathology

**DIFFERENTIAL**
- Differential diagnosis to rule out non-AD causes of cognitive impairment

**DIAGNOSE**
- Confirming AD pathology and determining treatment options

**TREAT & MONITOR**
- Initiating treatment and monitoring patient’s disease progression

**Vision**

To Improve patient outcomes among racial and ethnic minority populations with Alzheimer’s Disease

**Strategic Framework**

- Support data generation efforts to address unmet needs and data gaps of racial and ethnic minorities in AD
- Educate to drive understanding of the specific needs of racial and ethnic minorities in AD
- Collaborate with strategic partners to innovate solutions

**Goals / Guiding Principles**

A. Build Biogen Trust, Value, Engagement with Underserved Communities Globally
B. Increase underserved patient population clinical research awareness and participation
C. Expand publications and further studies of underserved patient populations in AD
D. Proactively identify and address gaps

**Establishing a Biogen AD-UP Advisory Council**

1. Gain feedback on the patient journey and specific obstacles for underserved patients with MCI/Mild AD
2. Identify research into AD pathology in African American and LatinX communities and areas of future focus
3. Identify key medical experts and topics for continued feedback to advise Biogen initiatives